SETD2 and renal carcinoma: For example, the SETD2 loss-of-function mutations were found in renal carcinoma [50, 51], lung cancer [52, 53], gastrointestinal cancer [54], and hematologic malignancies [55, 56], indicating that SETD2 is a tumor suppressor.